Indication intelligence, analysis and sector perception

Verastem Oncology (VSTM) priced a $150 M offering of 5% Convertible Senior Notes in a registered direct offering

October 14, 2018

Shares of VSTM closed down $0.58 or -9.31%% to $5.65 due to its selling millions worth of (unsecured) convertible notes due 2048; that might seem like a low interest rate to be paying for such a long term, but the note holders can convert the notes into 139.5771 shares for every $1,000 principal amount of the notes they own.

Audentes Therapeutics (BOLD) proposed a 5.2 M share offering with a 780 K share overallotment priced at $29.00

October 10, 2018

BOLD closed down -$6.88or -18.73% to $29.83 after Tuesday's +$0.37 to $36.70. With a 52 week change of +32.63% with ... ... 37.33 M shares outstanding and a float of 29.2 M shares – issue a -8.43% or 1.97 M share short ratio. 

Regenerative Medicine Earnings Scorecard - Q3/18 - to date

October 3, 2018

Q3/18 financial results also known as (AKA) earnings is a ‘scorecard’ of public stem, cell, gene therapies and editing, regenerative therapy and a couple of CNS and RNAi companies. The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position and "runways" for a better snapshot! By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.

What's Happening Today